<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880841</url>
  </required_header>
  <id_info>
    <org_study_id>20-A93-AU</org_study_id>
    <nct_id>NCT00880841</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone</brief_title>
  <official_title>A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoSHIFT LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoSHIFT LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg
      Buprenorphine/Naloxone.

      NIDA Contract No. HHSN271200577414C
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic profile of an investigational formulation of buprenorphine HCl/naloxone HCl 2mg/0.5mg oral capsules</measure>
    <time_frame>pk blood draws over a 72 hour period</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>phase 1a study for healthy normals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine / Naloxone</intervention_name>
    <description>oral formulation of buprenorphine / naloxone</description>
    <arm_group_label>no treatment</arm_group_label>
    <other_name>NanoBUP</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy normals between the ages of 18 and 55 (inclusive)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be a male or non-pregnant, non-breastfeeding female.

          -  Subject must be between 18 and 55 years of age (inclusive).

          -  Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and
             subject must weigh a minimum of 50 kg (110 lbs).

          -  Female subjects - not surgically sterile for at least 6 months or at least 2 years
             postmenopausal - must agree to utilize one of the following forms of contraception, if
             sexually active with a male partner, from screening through completion of the study.
             Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal,
             vaginal, or injection) in use at least 3 consecutive months prior to the first dose of
             study medication, double barrier (condom with spermicide; diaphragm with spermicide),
             intrauterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).

          -  Subject must voluntarily consent to participate in this study and provide their
             written informed consent prior to start of any study-specific procedures.

          -  Subject is willing and able to remain in the study unit for the entire duration of the
             confinement period and return for any outpatient visits.

        Exclusion Criteria:

          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, metabolic, dermatologic,
             neurologic, oncologic, or psychiatric disease or any other condition that, in the
             opinion of the Investigator, would jeopardize the safety of the subject or the
             validity of the study results.

          -  Has a clinically significant abnormal finding on the physical exam, medical history,
             ECG, or clinical laboratory results at screening.

          -  History or presence of allergic or adverse response to buprenorphine, naloxone,
             naltrexone, opioids, or any comparable or similar products.

          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose
             of study medication.

          -  Has donated blood or plasma within 30 days prior to the first dose of study
             medication.

          -  Has participated in another clinical trial within 30 days prior to the first dose of
             study medication.

          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,
             within 7 days prior to the first dose of study medication.

          -  Has used any prescription medication, except hormonal contraceptive or hormonal
             replacement therapy, within 14 days prior to the first dose of study medication.

          -  Has been treated with any known enzyme altering drugs, such as barbiturates,
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first
             dose of study medication.

          -  Has smoked or used tobacco products within 60 days prior to the first dose of study
             medication.

          -  Has history of substance abuse or dependence (including alcohol, opioids, or
             intravenous drug abuse)

          -  Is a female with a positive pregnancy test result.

          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, opiates).

          -  Has a positive urine alcohol test at screening or a positive ethanol breath test at
             check-in for the study period or has consumed alcohol within 48 hours prior to
             screening or check-in for the study period.

          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C, or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy normals, phase 1</keyword>
  <keyword>phase 1a study for healthy normals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

